Clinical Trial

The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2025 (before its estimated August 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to comprehensively assess the early and long-term effects of GLP-1 and GIP/GLP-1 analogue medications on metabolic and behavioral parameters, with particular emphasis on qualitative and quantitative dietary changes in patients undergoing treatment for overweight and obesity. Participation in the study will involve four follow-up visits per year at the Clinic of Diabetology and Internal Medicine, Central Clinical Hospital, University Clinical Clinical Hospital, Medical University of Warsaw: before treatment initiation and after 3, 6, and 12 months. The analysis will focus not only on metabolic effects (weight loss, changes in body composition, and improved biochemical parameters), but also on nutritional and behavioral aspects, including diet, appetite regulation, risk of malnutrition and muscle loss, and the occurrence of adverse events. The study will allow for a multifaceted assessment of the impact of treatment with GLP-1 and GIP/GLP-1 analogues on patients with excess body weight.
Trial Details
NCT Number NCT07270497
Lead Sponsor Medical University of Warsaw
Conditions GLP-1, Nutrition
Enrollment 100 participants
Start Date 2025-08-15
Primary Completion 2026-08-14 (estimated)
Study Completion 2026-08-14 (estimated)
Updated on ClinicalTrials.gov 2025-12-08